The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Open accessAbstract
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved to be a poor prognostic factor. In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+. PATIENTS AND METHODS: The European Myeloma Network, within the HARMONY project, collected individual data from 10,843 patients with NDMM enrolled in 16 clinical trials. An additive scoring system on the basis of top features predicting progression-free survival (PFS) and overall survival (OS) was developed and validated. RESULTS: In the training set (N = 7,072), at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. These variables were all simultaneously present in 2,226 patients. A value was assigned to each risk feature according to their OS impact (ISS-III 1.5, ISS-II 1, del(17p) 1, high lactate dehydrogenase 1, t(4;14) 1, and 1q+ 0.5 points). Patients were stratified into four risk groups according to the total additive score: low (Second Revision of the International Staging System [R2-ISS]-I, 19.2%, 0 points), low-intermediate (II, 30.8%, 0.5-1 points), intermediate-high (III, 41.2%, 1.5-2.5 points), high (IV, 8.8%, 3-5 points). Median OS was not reached versus 109.2 versus 68.5 versus 37.9 months, and median PFS was 68 versus 45.5 versus 30.2 versus 19.9 months, respectively. The score was validated in an independent validation set (N = 3,771, of whom 1,214 were with complete data to calculate R2-ISS) maintaining its prognostic value. CONCLUSION: The R2-ISS is a simple prognostic staging system allowing a better stratification of patients with intermediate-risk NDMM. The additive nature of this score fosters its future implementation with new prognostic variables.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045 · cited 2×
“917 (0) 750 (23) 585 (36) 437 (42) 326 (47) 252 (52) 188 (76) 133 (102) 83 (137) 47 (162) 24 (181) 195 (0) 141 (5) 93 (6) 63 (8) 45 (10) 32 (11) 26 (14) 20 (19) 10 (27) 7 (27) 3 (31) Time (months)”
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Self-citationCavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Self-citationAutologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Self-citationPalumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citationVoorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Self-citationMateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Self-citationA high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Self-citationPalumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423 · cited 4×
“135 (0) 129 (1) 126 (2) 122 (2) 113 (8) 94 (22) 75 (36) 44 (61) 21 (82) 6 (95) 0 (101) 322 (0) 297 (9) 290 (12) 266 (19) 233 (31) 181 (70) 136 (100) 92 (133) 50 (167) 12 (200) 0 (211) 627 (0) 540 (23) 485 (28) 424 (32) 351 (53) 271 (86) 205 (121) 139 (160) 70 (214) 12 (258) 1 (269) 130 (0) 106 (6) 80 (8) 68 (8) 47 (10…”
InfluentialSelf-citationUsmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381
Self-citationJackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 348
Self-citationGay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00389-7 · Cited by 314
Self-citationMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
Gay, F., Musto, P., Rota-Scalabrini, D., Bertamini, L., Belotti, A., Galli, M., Offidani, M., Zamagni, E., Ledda, A., Grasso, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00535-0 · Cited by 257
Self-citationCSG, O. B. O. T. N. H.-O., Shah, V, Sherborne, A. L., Walker, B. A., Johnson, D. C., Boyle, E. M., Ellis, S., Begum, D. B., Proszek, P. Z., Jones, J. R., et al. (2018) · Leukemia · doi:10.1038/leu.2017.179 · Cited by 235
Self-citationPalumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 211
Self-citationDimopoulos, M. A., Barlogie, B., Smith, T. L., & Alexanian, R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-12-931 · Cited by 208
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200
Self-citationDevelopment and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Perrot, A., Lauwers-Cances, V., Tournay, E., Hulin, C., Chretien, M.-L., Royer, B., Dib, M., Decaux, O., Jaccard, A., Belhadj, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00776 · Cited by 181
Palumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7561 · Cited by 173
Self-citationChromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 172
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 162
Schmidt, T. M., Barwick, B. G., Joseph, N., Heffner, L. T., Hofmeister, C. C., Bernal, L., Dhodapkar, M. V., Gupta, V. A., Jaye, D. L., Wu, J., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0254-0 · Cited by 162
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedè, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 158
Self-citationMai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 150
Self-citationTerpos, E., Katodritou, E., Ρούσσου, Μ., Pouli, A. G., Michalis, E., Delimpasi, S., Parcharidou, A., Kartasis, Z., Zomas, A., Symeonidis, A. S., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01466.x · Cited by 147
Mateos, M., Oriol, A., Martínez‐López, J., Gutierrez, N. C., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Polo, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-427815 · Cited by 143
Self-citationGarcés, J., Cedena, M., Puig, N., Burgos, L., Pérez, J. J., Cordón, L., Flores-Montero, J. A., Sanoja-Flores, L., Calasanz, M. J., Oriol, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01365 · Cited by 128
Self-citationZweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 124
Self-citationBelenkaya, R., Gurley, M. J., Golozar, A., Dymshyts, D., MILLER, R. T., Williams, A. E., Ratwani, S., Siapos, A., Korsik, V., Warner, J. L., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00079 · Cited by 112
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 110
Self-citationMateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Martínez, R., Palomera, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573733 · Cited by 104
Self-citationBertamini, L., Oliva, S., Rota‐Scalabrini, D., París, L., Morè, S., Corradini, P., Ledda, A., Gentile, M., Sabbata, G. D., Pietrantuono, G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01393 · Cited by 99
Self-citationMagarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 93
Self-citationWeinhold, N., Salwender, H. J., Cairns, D. A., Raab, M. S., Waldron, G., Blau, I. W., Bertsch, U., Hielscher, T., Morgan, G. J., Jauch, A. S., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278888 · Cited by 86
Self-citationGay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., Pezzatti, S., Ferrari, S., Liberati, A. M., Oliva, S., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483073 · Cited by 85
Self-citationD’Agostino, M., Zaccaria, G. M., Ziccheddu, B., Rustad, E. H., Genuardi, E., Capra, A., Oliva, S., Auclair, D., Yesil, J., Colucci, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0951 · Cited by 76
Self-citationMRD Assessment in Multiple Myeloma: Progress and Challenges
Bertamini, L., D’Agostino, M., & Gay, F. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00633-5 · Cited by 74
Self-citationGoldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0724-1 · Cited by 72
Self-citationMontefusco, V., Gay, F., Spada, S., Paoli, L. D., Raimondo, F. D., Ribolla, R., Musolino, C., Patriarca, F. F., Musto, P., Galieni, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219139 · Cited by 63
Self-citationTacchetti, P., Pantani, L., Patriarca, F. F., Petrucci, M. T., Zamagni, E., Dozza, L., Galli, M., Raimondo, F. D., Crippa, C., Boccadoro, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30323-9 · Cited by 63
Self-citationSequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Mateos, M., Martínez‐López, J., Hernández, M.-T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutierrez, N. C., Ramos, M.-L. M., Oriol, A., et al. (2015) · Blood · doi:10.1182/blood-2015-08-666537 · Cited by 61
Self-citationHow to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 58
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30167-x · Cited by 56
Self-citationImplications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Abdallah, N. H., Baughn, L. B., Rajkumar, S. V., Kapoor, P., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2283 · Cited by 55
Larocca, A., Bringhen, S., Petrucci, M. T., Oliva, S., Falcone, A. P., Caravita, T., Villani, O., Benevolo, G., Liberati, A. M., Morabito, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.36 · Cited by 45
Self-citationConsolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Sonneveld, P., Dimopoulos, M. A., Beksac, M., van der Holt, B., Aquino, S., Ludwig, H., Zweegman, S., Zander, T., Zamagni, E., Wester, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01045 · Cited by 44
Self-citationBringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 43
Self-citationJackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.247130 · Cited by 40
Self-citationTandon, N., Rajkumar, S. V., LaPlant, B. R., Pettinger, A. M., Lacy, M. Q., Dispenzieri, A. A., Buadi, F. K., Gertz, M. A., Hayman, S. R., Leung, N., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.13 · Cited by 37
Jackson, G. H., Pawlyn, C., Cairns, D. A., Tute, R. M. D., Hockaday, A., Collett, C., Jones, J. R., Kishore, B., Garg, M. K., Williams, C. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003454 · Cited by 37
Self-citationKuiper, R., Zweegman, S., van Duin, M., van Vliet, M. H., van Beers, E. H., Dumee, B., Vermeulen, M., Koenders, J. E., van der Holt, B., Visser-Wisselaar, H. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002838 · Cited by 36
Self-citationMina, R., Joseph, N. S., Gay, F., Kastritis, E., Petrucci, M. T., Kaufman, J. L., Montefusco, V., Gavriatopoulou, M., Patriarca, F. F., Omedè, P., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0307-4 · Cited by 35
Self-citationA multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Goldman‐Mazur, S., Jurczyszyn, A. J., Castillo, J. J., Waszczuk‐Gajda, A., Grząśko, N., Radocha, J., Bittrich, M., Kortüm, K. M., Gozzetti, A., Usnarska‐Zubkiewicz, L., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25758 · Cited by 33
Self-citationCaltagirone, S., Ruggeri, M., Aschero, S., Gilestro, M., Oddolo, D., Gay, F., Bringhen, S., Musolino, C., Baldini, L., Musto, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.103853 · Cited by 23
Self-citationJackson, G. H., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Wilson, J. N., Taylor, C., Kishore, B., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16945 · Cited by 19
Self-citation
Cited by
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, F., Rajanna, A. R., Ziccheddu, B., Poos, A. M., Derkach, A., Maclachlan, K., Durante, M., Diamond, B., Papadimitriou, M., Davies, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01277 · Cited by 131
Self-citationTemporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14
Self-citation
Metadata
- Authors
- D'Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M.-V., Dall'Olio, D., van de Donk, N. W. C. J., Jackson, G., Rocchi, S., Salwender, H., Bladé Creixenti, J., van der Holt, B., Castellani, G., Bonello, F., Capra, A., Mai, E. K., Dürig, J., Gay, F., Zweegman, S., Cavo, M., Kaiser, M. F., Goldschmidt, H., Hernández Rivas, J. M., Larocca, A., Cook, G., San-Miguel, J. F., Boccadoro, M., & Sonneveld, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-10-10
- Volume
- 40
- Issue
- 29
- Pages
- 3406-3418
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4281397013
- Cited by
- 429
- References
- 63
- FWCI
- 54.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.